redefining precision molecular diagnostics through
diacarta, inc. | redefining precision molecular diagnostics through cancer mutation detection-凯时尊龙官网
diacarta is a leading translational genomics and personalized diagnostics company based in richmond, california with significant business operations in china. diacarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.
hpv mrna screening
ngs targeted sequencing
clia lab service
ultra-sensitive
xna technology
xna,
ultra-sensitive
superbdna™ technology
superbdna™ technology uses branched dna to qualitatively or quantitatively measure the presence of target dna or rna. unlike pcr or rt-pcr, superbdna™ technology does not amplify the dna or rna in the samples, rather amplifies the signals for detection. because the amplified signal is proportional to the levels of the target (dna or rna) in the samples, the latter is easy to be quantified with a standard curve. superbdna™ technology has been used in fda-approved clinical applications, including prognosis and monitoring of patients with viral diseases.
diacarta announced that cio bulletin has named it among the 30 fastest growing companies of 2018. the positioning is based on diacarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to forecast future business and technology trends.
next-generation sequencing (ngs) is a powerful tool that has seen a fast increase in clinical labs although only a few ngs tests have been approved by the fda. however, there have been a lot of debate on if variants from ngs sequencing should be confirmed either by sanger sequencing, the gold standard, or other techniques such as quantitative pcr, or the combination, or other methods.
next-generation sequencing (ngs) is a powerful tool that has seen a fast increase in clinical labs although only a few ngs tests have been approved by the fda. however, there have been a lot of debate on if variants from ngs sequencing should be confirmed either by sanger sequencing, the gold standard, or other techniques such as quantitative pcr, or the combination, or other methods.